Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Outlook Therapeutics, Inc. (OTLK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2000+0.0500 (+4.35%)
At close: 04:00PM EDT
1.1700 -0.03 (-2.50%)
After hours: 07:57PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close1.1500
Open1.2100
Bid1.1700 x 3200
Ask1.2500 x 1800
Day's Range1.1700 - 1.2100
52 Week Range0.6840 - 2.8650
Volume288,130
Avg. Volume922,390
Market Cap271.374M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)-0.3220
Earnings DateAug 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.58
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OTLK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Outlook Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 03/03/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • GlobeNewswire

    Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones

    Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on track ISELIN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced its financial results for its fiscal third quarter ended June 30, 2022, pr

  • GlobeNewswire

    Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference

    ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the H.C. Wainwright 2nd Annual Ophthalmology Conference being held virtually on Wednesday, August 17. In addition to the presenta

  • Simply Wall St.

    When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable?

    We feel now is a pretty good time to analyse Outlook Therapeutics, Inc.'s ( NASDAQ:OTLK ) business as it appears the...

Advertisement
Advertisement